Conexiant
Login
  • Corneal Physician
  • Glaucoma Physician
  • New Retinal Physician
  • Ophthalmology Management
  • Ophthalmic Professional
  • Presbyopia Physician
  • Retinal Physician
The Ophthalmologist
  • Explore

    Explore

    • Latest
    • Insights
    • Case Studies
    • Opinion & Personal Narratives
    • Research & Innovations
    • Product Profiles

    Featured Topics

    • Anterior Segment
    • Glaucoma
    • Retina

    Issues

    • Latest Issue
    • Archive
  • Subspecialties
    • Cataract
    • Cornea
    • Glaucoma
    • Neuro-ophthalmology
    • Oculoplastics
    • Pediatric
    • Retina
  • Business

    Business & Profession

    • Professional Development
    • Business and Entrepreneurship
    • Practice Management
    • Health Economics & Policy
  • Training & Education

    Career Development

    • Professional Development
    • Career Pathways

    Events

    • Webinars
    • Live Events
  • Events
    • Live Events
    • Webinars
  • Community

    People & Profiles

    • Power List
    • Voices in the Community
    • Authors & Contributors
  • Multimedia
    • Video
    • Podcasts
Subscribe
Subscribe

False

Advertisement
The Ophthalmologist / Issues / 2022 / Jun / Clearing the Path
Anterior Segment Cataract Research & Innovations Business and Entrepreneurship

Clearing the Path

Is treating cataracts without surgery a reasonable vision of the future?

By Oscelle Boye 6/22/2022 1 min read

Share

Credit: Images by Aleksandra Jones.

We all know that life has its inevitabilities (try not to think of death and taxes), but does surgical intervention in cataract treatment need to be one of them? Researchers have recently been exploring the effects of topically administered oxysterol compounds on the optics of the lens. Oxysterol compounds have previously been found to interact with proteins essential for lens transparency, and as a result have been touted as potential anti-cataracts drugs.

As Barbara Pierscionek, Deputy Dean of Research and Innovation a the Anglia Ruskin University, Chelmsford, UK, and leader of the international group of scientists conducting the study, explains, “The structural effect of oxysterol compounds on the lens have been examined in the past, but their effect on the functional aspects, the optics, which are critical to vision, have not been considered.” In this pioneering study, the researchers observed that treating a murine model of cataracts with the oxysterol compound VP1-001 resulted in an improvement in refractive index profiles in the majority of lenses and a reduction in the lens opacity in nearly half of all cases (1).

Yes, the results have only been shown in mice, but there’s no denying the hope – even promise – of a simpler, less invasive alternative to surgery. And Pierscionek and her team will continue to pursue that very goal. “We will continue to investigate VP1-001 and other compounds to determine which are the most effective for treating the different forms of cataracts,” she says. “I would like to see [our work] improve the treatments offered for cataracts globally and, in particular, those offered in developing countries, helping those who lack access to current surgery or care.”

References

  1. K Wang et al., Invest Ophthalmol Vis Sci., 63, 15 (2022), PMID: 35575904.

About the Author(s)

Oscelle Boye

I have always been fascinated by stories. During my biomedical sciences degree, though I enjoyed wet lab sessions, I was truly in my element when sitting down to write up my results and find the stories within the data. Working at Texere gives me the opportunity to delve into a plethora of interesting stories, sharing them with a wide audience as I go.

More Articles by Oscelle Boye

Related Content

Newsletters

Receive the latest Ophthalmology news, personalities, education, and career development – weekly to your inbox.

Newsletter Signup Image

False

Advertisement

False

Advertisement

Explore More in Ophthalmology

Dive deeper into the world of Ophthalmology. Explore the latest articles, case studies, expert insights, and groundbreaking research.

False

Advertisement
The Ophthalmologist
Subscribe

About

  • About Us
  • Work at Conexiant Europe
  • Terms and Conditions
  • Privacy Policy
  • Advertise With Us
  • Contact Us

Copyright © 2025 Texere Publishing Limited (trading as Conexiant), with registered number 08113419 whose registered office is at Booths No. 1, Booths Park, Chelford Road, Knutsford, England, WA16 8GS.

Disclaimer

The Ophthalmologist website is intended solely for the eyes of healthcare professionals. Please confirm below: